METEL Study Which is to Collect Urine Samples From Patients to Analyse Their Chemistry to Assess How Close to Death the Patient is at Point of Sample When They Have a Solid Cancer Tumour Diagnosis

NCT07848997 | Recruiting

• 1 other identifier: 337603
• Study Type: observational
• Target: 1,327
• Locations: 1 country
• Sites: 1

Brief Summary

Use of samples from patients with solid cancer tumour diagnosis to assess chemistry

Conditions

Solid Tumor Cancer

Keywords

Solid Cancer Tumour

Outcome Measures

Primary Outcomes (1)

• Study Outcome

  This work could identify mechanisms involved in the dying process and develop test predicting time until death. Understanding of the biology of dying will improve the recognition of people in the last days and weeks of life. This will; - - Improve the quality of a person's death by reducing uncertainty and facilitating preferred place of care. Reduce healthcare spending on futile diagnostic and therapeutic interventions. We will correct urine samples once per week from participants, to be able to analyse their metabolites for changes towards end of life.

  18 months

Study Arms (1)

Solid Tumour Cancer

Solid Tumour Cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a solid tumour cancer diagnosis

You may qualify if:

• Must have as solid cancer tumour diagnosis Must be over the age of 18 Must be able to understand and communicate in English Must be able to provide fully informed consent at the point of trial entry Must be able to urinate freely or be catheterised

You may not qualify if:

• Does not have a solid cancer tumour diagnosis Under the age of 18 Unable to communicate and understand English Unable to provide fully informed consent at the point of trial entry Is no cathetherised or able to urinate freely

Sponsors & Collaborators

• The Clatterbridge Cancer Centre NHS Foundation Trust: lead

Study Sites (1)

Clatterbridge Cancer Centre

Liverpool, Merseyside, L7 8YA, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Urine

Central Study Contacts

Seamus Coyle Principal Investigator

CONTACT

0151 556 5060; s.coyle@liverpool.ac.uk

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 7, 2026
• First Posted: September 30, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): February 28, 2028
• Study Completion (Estimated): February 28, 2028
• Last Updated: September 30, 2026

Record last verified: 2026-09

Locations

GB (1)